Reported by ScienceDaily
Popular medications used to treat obesity and type 2 diabetes, including semaglutide and tirzepatide, may have effects that extend beyond weight loss and blood sugar control. These drugs also influence biological processes involved in brain function, raising questions about whether they could help preserve memory and thinking abilities.
To examine this possibility, researchers from the University of Gothenburg and the University of Copenhagen reviewed the existing scientific evidence at the invitation of the journal Science .
Studies involving animals suggest that GLP-1 medications can influence learning and memory. However, research involving humans has produced less consistent findings. Analyses of patient health records have found an association between GLP-1 treatment and a reduced risk of dementia among people with type 2 diabetes. These observational findings are encouraging, but they cannot determine whether the medications themselves are responsible for the lower risk.
More from the original report
More definitive results have also raised questions. In Novo Nordisk's EVOKE and EVOKE+ clinical trials, semaglutide failed to slow the progression of early Alzheimer's disease. Although the treatment affected several biological markers associated with Alzheimer's, those changes did not translate into a measurable slowing of the disease.
Despite the disappointing Alzheimer's results, researchers believe GLP-1 medications could still offer cognitive benefits to certain groups of patients.
People living with obesity or type 2 diabetes sometimes experience difficulties with attention, planning, and the speed at which they process information. These cognitive problems are often associated with metabolic health and blood vessel function, suggesting they may respond differently to treatment than the changes caused by Alzheimer's disease.
Improving blood sugar regulation, metabolism, or vascular health could potentially help preserve cognitive abilities, even if the same medications cannot slow an established neurodegenerative disease.
Stina Börchers, the review's first author and a researcher affiliated with both the University of Gothenburg and the University of Copenhagen, emphasizes the need to determine whether starting treatment earlier could make a difference.
"We need to find out whether these treatments can help people with obesity or diabetes preserve their cognitive abilities, particularly if treatment begins before cognitive problems become established. It is also important to identify which patients…
